{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T20:47:47Z","timestamp":1791146867338,"version":"4.1.0"},"reference-count":35,"publisher":"Cambridge University Press (CUP)","issue":"4","license":[{"start":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T00:00:00Z","timestamp":1384300800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/www.cambridge.org\/core\/terms"}],"content-domain":{"domain":["www.cambridge.org"],"crossmark-restriction":true},"short-container-title":["Acta Neuropsychiatr."],"published-print":{"date-parts":[[2014,8]]},"abstract":"<jats:sec id=\"S0924270813000550_abs1\" sec-type=\"general\"><jats:title>Introduction and Hypothesis<\/jats:title><jats:p>Some authors draw a connection between the dopaminergic pathways and emotional perception. The present study is based on that association and addresses the question whether methylphenidate and the resulting amelioration of the disturbed dopamine metabolism lead to an improvement of the facial affect recognition abilities in children with attention-deficit\/hyperactivity disorder (ADHD).<\/jats:p><\/jats:sec><jats:sec id=\"S0924270813000550_abs2\" sec-type=\"methods\"><jats:title>Methods<\/jats:title><jats:p>A computer test was conducted on 21 participants, aged 7<jats:italic>\u2013<\/jats:italic>14 years and with a diagnosis of ADHD \u2013 some with comorbid oppositional defiant disorder \u2013 conducted the FEFA (Frankfurt Test and Training of Facial Affect), a computer test to examine their facial affect recognition abilities. It consists of two subtests, one with faces and one with eye pairs. All participants were tested in a double-blind cross-over study, once under placebo and once under methylphenidate.<\/jats:p><\/jats:sec><jats:sec id=\"S0924270813000550_abs3\" sec-type=\"results\"><jats:title>Results and Discussion<\/jats:title><jats:p>The collected data showed that methylphenidate leads to amelioration of facial affect recognition abilities, but not on a significant level. Reasons for missing significance may be the small sample size or the fact that there exists some overlapping in cerebral connections and metabolic pathways of the site of action of methylphenidate and the affected dopaminergic areas in ADHD. However, consistent with the endophenotype concept, certain gene locations of the dopaminergic metabolism as both an aetiological factor for ADHD and the deficient facial affect recognition abilities with these individuals were considered. Consulting current literature they were found to be not concordant. Therefore, we conclude that the lacking significance of the methylphenidate affect on facial affect recognition is based on this fact.<\/jats:p><\/jats:sec>","DOI":"10.1017\/neu.2013.55","type":"journal-article","created":{"date-parts":[[2013,11,13]],"date-time":"2013-11-13T05:51:38Z","timestamp":1384321898000},"page":"202-208","update-policy":"https:\/\/doi.org\/10.1017\/policypage","source":"Crossref","is-referenced-by-count":20,"title":["Improvement of facial affect recognition in children and adolescents with attention-deficit\/hyperactivity disorder under methylphenidate"],"prefix":"10.1017","volume":"26","author":[{"given":"Sophie","family":"Beyer von Morgenstern","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Sinzig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"56","published-online":{"date-parts":[[2013,11,13]]},"reference":[{"key":"S0924270813000550_ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s10802-006-9096-x"},{"key":"S0924270813000550_ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-007-0637-9"},{"key":"S0924270813000550_ref31","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291706008750"},{"key":"S0924270813000550_ref25","doi-asserted-by":"publisher","DOI":"10.1080\/13803390802119930"},{"key":"S0924270813000550_ref19","doi-asserted-by":"crossref","DOI":"10.1201\/9781420036091","volume-title":"Design and Analysis of Cross-over-Trials","author":"Jones","year":"2003"},{"key":"S0924270813000550_ref32","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.160.4.636"},{"key":"S0924270813000550_ref14","doi-asserted-by":"publisher","DOI":"10.1046\/j.1471-4159.1997.68052032.x"},{"key":"S0924270813000550_ref15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1523\/JNEUROSCI.21-02-j0001.2001","article-title":"Therapeutic doses of oral methylphenidate significantly increase extracellular dopamine in the human brain","volume":"21","author":"Volkow","year":"2001","journal-title":"Journal Neurosci"},{"key":"S0924270813000550_ref27","doi-asserted-by":"publisher","DOI":"10.1080\/00207450601125907"},{"key":"S0924270813000550_ref2","unstructured":"World Health Organisation. International Classification of Diseases, 10th Revision. Chapter V, Mental and Behavioral Disorders, 1992."},{"key":"S0924270813000550_ref4","first-page":"217","article-title":"Sex and age differences in attention-deficit\/hyperactivity disorder symptoms and diagnoses: implications for DSM-V and ICD-11","volume":"49","author":"Ramtekkar","year":"2010","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"S0924270813000550_ref18","first-page":"61","article-title":"The development and evaluation of a computer-based program to test and to teach the recognition of facial affect","volume":"61","author":"Boelte","year":"2002","journal-title":"Int J Circumpolar Health"},{"key":"S0924270813000550_ref13","doi-asserted-by":"publisher","DOI":"10.1016\/0024-3205(96)00052-5"},{"key":"S0924270813000550_ref24","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/114.6.2593"},{"key":"S0924270813000550_ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s00787-008-1006-z"},{"key":"S0924270813000550_ref22","doi-asserted-by":"publisher","DOI":"10.1159\/000329555"},{"key":"S0924270813000550_ref7","doi-asserted-by":"publisher","DOI":"10.1111\/j.1469-7610.1997.tb01599.x"},{"key":"S0924270813000550_ref1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1021729501230"},{"key":"S0924270813000550_ref12","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.56.12.1073"},{"key":"S0924270813000550_ref9","doi-asserted-by":"publisher","DOI":"10.1017\/S0954579499001947"},{"key":"S0924270813000550_ref35","doi-asserted-by":"publisher","DOI":"10.1024\/1422-4917.34.5.357"},{"key":"S0924270813000550_ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2008.02.025"},{"key":"S0924270813000550_ref30","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.b.30182"},{"key":"S0924270813000550_ref21","doi-asserted-by":"publisher","DOI":"10.1177\/01454455920164006"},{"key":"S0924270813000550_ref6","doi-asserted-by":"publisher","DOI":"10.1017\/S0140525X00076512"},{"key":"S0924270813000550_ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropharm.2009.08.013"},{"key":"S0924270813000550_ref33","doi-asserted-by":"publisher","DOI":"10.1007\/s00115-003-1642-y"},{"key":"S0924270813000550_ref29","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.158.7.1052"},{"key":"S0924270813000550_ref28","doi-asserted-by":"publisher","DOI":"10.1111\/j.1467-7687.2011.01124.x"},{"key":"S0924270813000550_ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2007.11.022"},{"key":"S0924270813000550_ref34","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-9877(02)00406-1"},{"key":"S0924270813000550_ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00431-006-0299-5"},{"key":"S0924270813000550_ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuropsychologia.2006.08.003"},{"key":"S0924270813000550_ref23","doi-asserted-by":"publisher","DOI":"10.1016\/0028-3932(86)90050-3"},{"key":"S0924270813000550_ref17","doi-asserted-by":"publisher","DOI":"10.1097\/01.wnf.0000185824.57690.f0"}],"container-title":["Acta Neuropsychiatrica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cambridge.org\/core\/services\/aop-cambridge-core\/content\/view\/S0924270813000550","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T14:19:04Z","timestamp":1564669144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cambridge.org\/core\/product\/identifier\/S0924270813000550\/type\/journal_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,13]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["S0924270813000550"],"URL":"https:\/\/doi.org\/10.1017\/neu.2013.55","relation":{},"ISSN":["0924-2708","1601-5215"],"issn-type":[{"value":"0924-2708","type":"print"},{"value":"1601-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,13]]},"assertion":[{"value":"Copyright \u00a9 Scandinavian College of Neuropsychopharmacology 2013\u00a0","name":"license","label":"License","group":{"name":"copyright_and_licensing","label":"Copyright and Licensing"}}]}}